Adipotide

CKGGRAKDC-GG-D(KLAKLAK)2 (Fat Cell Targeting)

Ask AI About This

Amino Acids

N/A

Molecular Weight

~2,500 Da

Half-life

~hours (estimated)

Research Score

3.5

Studies

Storage

N/A

What is Adipotide?

Adipotide is a peptidomimetic that targets and destroys the blood supply to fat tissue (adipose vasculature). It uses a homing sequence to find blood vessels feeding white fat cells and a proapoptotic sequence to destroy them. Studied for rapid, targeted fat loss in primate models.

Key Benefits & Mechanisms

Targeted fat cell destruction

Rapid fat loss in primate studies

Selective for white adipose tissue

Does not affect other tissues

Significant weight reduction in animal models

Unique mechanism of action

Potential for spot reduction

Research Summary

Adipotide showed dramatic fat loss results in rhesus monkeys (11% body weight in 4 weeks). However, renal toxicity was observed, limiting clinical development. The concept of vascular targeting for fat reduction is novel. Significant safety hurdles remain before human use.

Related Peptides

Semaglutide

GLP-1 Receptor Agonist

Semaglutide is a GLP-1 receptor agonist with proven efficacy for weight management and glycemic control. FDA-approved as Ozempic (diabetes) and Wegovy (weight management), it mimics the incretin hormone GLP-1 to regulate appetite and blood sugar.

Metabolic

Tirzepatide

GIP/GLP-1 Dual Receptor Agonist

Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight management). It offers superior weight loss compared to GLP-1-only agonists by targeting two incretin pathways simultaneously.

Metabolic

AOD-9604

Anti-Obesity Drug (Modified GH Fragment)

AOD-9604 is a modified fragment of human growth hormone (HGH fragment 177-191) specifically designed for fat metabolism. It stimulates lipolysis and inhibits lipogenesis without affecting blood sugar or tissue growth, making it a targeted fat-loss peptide without typical GH side effects.

Metabolic

Tesamorelin

Synthetic Growth Hormone Releasing Hormone

Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved as Egrifta for HIV-associated lipodystrophy, it reduces visceral adipose tissue while maintaining peripheral fat and improving body composition. Produces physiological GH release.

Metabolic